Metastatic colorectal cancer: To stop or not to stop?

Pascal Artru; Jaafar Bennouna; Astrid Lievre; Michel Ducreux; Gérard Lledo

doi:10.1016/j.bulcan.2017.12.010

Metastatic colorectal cancer: To stop or not to stop?

Titre traduit de la contribution: Cancer colorectal métastatique: place du traitement d'entretien et de la pause thérapeutique

Pascal Artru, Jaafar Bennouna, Astrid Lievre, Michel Ducreux, Gérard Lledo

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

2 Citations (Scopus)

Résumé

The introduction of new regimens and targeted therapies has prolonged survival in metastatic colorectal cancer from 1 year during the fluoropyrimidines-only era to more than 30 months today. Avoiding the cumulative toxicity of oxaliplatin, but also the physical or psychological asthenia of prolonged chemotherapy, is currently a worthwhile management goal. Data from randomized controlled trials indicate that a formalized stop-and-go approach to the delivery of oxaliplatin does not compromise efficacy. This paper presents also a critical review of the randomized trials evaluating the place of bevacizumab and cetuximab as maintenance therapy. To conclude we recommend chemotherapy holidays only after 4 to 6 months of chemotherapy and only in the population of very good responders to the induction treatment.

Titre traduit de la contribution	Cancer colorectal métastatique: place du traitement d'entretien et de la pause thérapeutique
langue originale	Anglais
Pages (de - à)	408-414
Nombre de pages	7
journal	Bulletin du Cancer
Volume	105
Numéro de publication	4
Les DOIs	https://doi.org/10.1016/j.bulcan.2017.12.010
état	Publié - 1 avr. 2018

Accès au document

10.1016/j.bulcan.2017.12.010

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6dbc9ceb58b94fb3b120166c290390a9,

title = "Metastatic colorectal cancer: To stop or not to stop?",

abstract = "The introduction of new regimens and targeted therapies has prolonged survival in metastatic colorectal cancer from 1 year during the fluoropyrimidines-only era to more than 30 months today. Avoiding the cumulative toxicity of oxaliplatin, but also the physical or psychological asthenia of prolonged chemotherapy, is currently a worthwhile management goal. Data from randomized controlled trials indicate that a formalized stop-and-go approach to the delivery of oxaliplatin does not compromise efficacy. This paper presents also a critical review of the randomized trials evaluating the place of bevacizumab and cetuximab as maintenance therapy. To conclude we recommend chemotherapy holidays only after 4 to 6 months of chemotherapy and only in the population of very good responders to the induction treatment.",

keywords = "Chemotherapy-holidays, Induction chemotherapy, Maintenance, Stop-and-go",

author = "Pascal Artru and Jaafar Bennouna and Astrid Lievre and Michel Ducreux and G{\'e}rard Lledo",

note = "Publisher Copyright: {\textcopyright} 2018 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer",

year = "2018",

month = apr,

day = "1",

doi = "10.1016/j.bulcan.2017.12.010",

language = "English",

volume = "105",

pages = "408--414",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "4",

}

TY - JOUR

T1 - Metastatic colorectal cancer

T2 - To stop or not to stop?

AU - Artru, Pascal

AU - Bennouna, Jaafar

AU - Lievre, Astrid

AU - Ducreux, Michel

AU - Lledo, Gérard

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The introduction of new regimens and targeted therapies has prolonged survival in metastatic colorectal cancer from 1 year during the fluoropyrimidines-only era to more than 30 months today. Avoiding the cumulative toxicity of oxaliplatin, but also the physical or psychological asthenia of prolonged chemotherapy, is currently a worthwhile management goal. Data from randomized controlled trials indicate that a formalized stop-and-go approach to the delivery of oxaliplatin does not compromise efficacy. This paper presents also a critical review of the randomized trials evaluating the place of bevacizumab and cetuximab as maintenance therapy. To conclude we recommend chemotherapy holidays only after 4 to 6 months of chemotherapy and only in the population of very good responders to the induction treatment.

AB - The introduction of new regimens and targeted therapies has prolonged survival in metastatic colorectal cancer from 1 year during the fluoropyrimidines-only era to more than 30 months today. Avoiding the cumulative toxicity of oxaliplatin, but also the physical or psychological asthenia of prolonged chemotherapy, is currently a worthwhile management goal. Data from randomized controlled trials indicate that a formalized stop-and-go approach to the delivery of oxaliplatin does not compromise efficacy. This paper presents also a critical review of the randomized trials evaluating the place of bevacizumab and cetuximab as maintenance therapy. To conclude we recommend chemotherapy holidays only after 4 to 6 months of chemotherapy and only in the population of very good responders to the induction treatment.

KW - Chemotherapy-holidays

KW - Induction chemotherapy

KW - Maintenance

KW - Stop-and-go

UR - http://www.scopus.com/inward/record.url?scp=85042294572&partnerID=8YFLogxK

U2 - 10.1016/j.bulcan.2017.12.010

DO - 10.1016/j.bulcan.2017.12.010

M3 - Review article

C2 - 29477654

AN - SCOPUS:85042294572

SN - 0007-4551

VL - 105

SP - 408

EP - 414

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 4

ER -